Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.4.0.3
Segments
3 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We currently manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of Bio-Reference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2016
 
2015
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
252,522

 
2,009

Corporate

 
60

 
$
252,522

 
$
2,069

Product revenues:
 
 
 
Pharmaceutical
$
19,899

 
$
15,486

Diagnostics

 

Corporate

 

 
$
19,899

 
$
15,486

Revenue from transfer of intellectual property:
 
 
 
Pharmaceutical
$
18,616

 
$
12,529

Diagnostics

 

Corporate

 

 
$
18,616

 
$
12,529

Operating (loss) income:
 
 
 
Pharmaceutical
$
(1,330
)
 
$
(37,924
)
Diagnostics
(2,355
)
 
(8,477
)
Corporate
(23,833
)
 
(9,979
)
Less: Operating loss attributable to noncontrolling interests

 
(534
)
 
$
(27,518
)
 
$
(56,914
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
2,861

 
$
1,756

Diagnostics
19,320

 
1,747

Corporate
18

 
22

 
$
22,199

 
$
3,525

Net loss from investment in investees:
 
 
 
Pharmaceutical
$
(2,050
)
 
$
(1,761
)
Diagnostics
(295
)
 

Corporate

 

 
$
(2,345
)
 
$
(1,761
)
Revenues:
 
 
 
United States
$
252,438

 
$
2,493

Ireland
22,144

 
12,104

Chile
6,983

 
6,452

Spain
4,023

 
3,937

Israel
4,743

 
4,213

Mexico
706

 
885

 
$
291,037

 
$
30,084


(In thousands)
March 31,
2016
 
December 31,
2015
Assets:
 
 
 
Pharmaceutical
$
1,246,467

 
$
1,234,752

Diagnostics
1,435,297

 
1,421,034

Corporate
111,442

 
143,402

 
$
2,793,206

 
$
2,799,188

Goodwill:

 

Pharmaceutical
$
255,159

 
$
251,225

Diagnostics
491,802

 
492,123

Corporate

 

 
$
746,961

 
$
743,348



During the three months ended March 31, 2016 and 2015, revenue recognized under the Pfizer Transaction represented 6% and 42% of our total revenue. Refer to Note 12. As of March 31, 2016 and December 31, 2015, one customer represented more than 10% of our accounts receivable balance.